Skip to main content

Can you take Capivasertib with Flibanserin?

1 drug interaction and 12 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Moderate drug interactions

Moderate:

flibanserin capivasertib

Applies to: flibanserin and capivasertib

Capivasertib may increase the blood levels of flibanserin.

In some cases, this may increase the risk of side effects such as drowsiness and decreases in blood pressure that can lead to:

  • dizziness
  • lightheadedness
  • fainting
  • accidental injury

You should take flibanserin at bedtime to minimize the risk of these effects.

Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications.

It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Food/lifestyle interactions

Major food/lifestyle interactions

Major:

flibanserin Food/Lifestyle

Applies to: flibanserin

Do not use alcohol too close to the dosing time of flibanserin. Doing so can cause excessive drowsiness and decreases in blood pressure, which may lead to:

  • dizziness
  • lightheadedness
  • fainting
  • accidental injury

What to do: Take flibanserin at bedtime to minimize the risk of these effects. It is recommended that you stop drinking alcohol at least two hours before taking flibanserin; otherwise, you should just skip the flibanserin dose that evening. Alcohol should not be consumed until at least the morning after taking flibanserin at bedtime.

Because grapefruit juice can significantly increase the blood levels of flibanserin, you should also avoid the consumption of grapefruit and grapefruit juice during treatment.

Talk to your healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Major:

capivasertib Food/Lifestyle

Applies to: capivasertib

Consumption of grapefruit, grapefruit juice, and supplements that contain grapefruit should be avoided during treatment with capivasertib as they may increase the blood levels of capivasertib.

This may increase the risk of side effects such as:

  • high blood sugar levels
  • diarrhea
  • skin reactions
  • nausea
  • vomiting
  • tiredness
  • changes in certain blood tests

Talk to your doctor if you have any questions or concerns.

It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Disease interactions

10 potential interactions Applies to: 9 conditions, including Type 2 Diabetes, Hypotension, Diabetes, Type 1, Diabetes Mellitus, and Syncope.

Alcoholism

Major:

flibanserin

Flibanserin has a major potential interaction with Alcoholism.

The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope. It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.

Diabetes, Type 1

Moderate:

capivasertib

Capivasertib has a moderate potential interaction with Diabetes, Type 1.

Severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes, has occurred in patients treated with capivasertib. The safety of capivasertib in patients with Type 1 diabetes or with diabetes requiring insulin has not been established; these patients were excluded from clinical studies. Fasting blood glucose and hemoglobin A1C should be evaluated and optimized before starting treatment. Regular monitoring of fasting blood glucose as recommended by the manufacturer should be performed during treatment with capivasertib. Consider consultation with a specialist in the treatment of hyperglycemia and initiation of fasting glucose monitoring at home for patients who have risk factors for or who experience hyperglycemia. If hyperglycemia occurs during treatment, the dose of capivasertib may need to be withheld or reduced, or treatment permanently discontinued based on severity or if ketoacidosis is confirmed.

Diabetes Mellitus

Moderate:

capivasertib

Capivasertib has a moderate potential interaction with Diabetes Mellitus.

Severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes, has occurred in patients treated with capivasertib. The safety of capivasertib in patients with Type 1 diabetes or with diabetes requiring insulin has not been established; these patients were excluded from clinical studies. Fasting blood glucose and hemoglobin A1C should be evaluated and optimized before starting treatment. Regular monitoring of fasting blood glucose as recommended by the manufacturer should be performed during treatment with capivasertib. Consider consultation with a specialist in the treatment of hyperglycemia and initiation of fasting glucose monitoring at home for patients who have risk factors for or who experience hyperglycemia. If hyperglycemia occurs during treatment, the dose of capivasertib may need to be withheld or reduced, or treatment permanently discontinued based on severity or if ketoacidosis is confirmed.

Diabetic Ketoacidosis

Moderate:

capivasertib

Capivasertib has a moderate potential interaction with Diabetic Ketoacidosis.

Severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes, has occurred in patients treated with capivasertib. The safety of capivasertib in patients with Type 1 diabetes or with diabetes requiring insulin has not been established; these patients were excluded from clinical studies. Fasting blood glucose and hemoglobin A1C should be evaluated and optimized before starting treatment. Regular monitoring of fasting blood glucose as recommended by the manufacturer should be performed during treatment with capivasertib. Consider consultation with a specialist in the treatment of hyperglycemia and initiation of fasting glucose monitoring at home for patients who have risk factors for or who experience hyperglycemia. If hyperglycemia occurs during treatment, the dose of capivasertib may need to be withheld or reduced, or treatment permanently discontinued based on severity or if ketoacidosis is confirmed.

Hypotension

Major:

flibanserin

Flibanserin has a major potential interaction with Hypotension.

The use of flibanserin can cause hypotension and syncope. The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension. Flibanserin should be used with caution in these patients.

Liver Disease

Major:

flibanserin

Flibanserin has a major potential interaction with Liver Disease.

Flibanserin may accumulate in patients with hepatic impairment. Therapy with flibanserin is contraindicated in patients with compromised hepatic function.

Moderate:

capivasertib

Capivasertib has a moderate potential interaction with Liver Disease.

Capivasertib has not been studied in patients with severe hepatic impairment (bilirubin greater than 3 times ULN and any AST). In patients with moderate hepatic impairment (bilirubin greater than 1.5 to 3 times ULN and any AST), additional monitoring for adverse side effects is recommended due to the potential for increased exposure. No dose adjustment is recommended in patients with mild hepatic impairment.

Renal Dysfunction

Moderate:

capivasertib

Capivasertib has a moderate potential interaction with Renal Dysfunction.

Capivasertib has not been studied in patients with severe renal dysfunction (CrCl 15 to 29 mL/min). No dose adjustment is recommended in patients with mild to moderate renal dysfunction (CrCl 30 to 89 mL/min).

Syncope

Major:

flibanserin

Flibanserin has a major potential interaction with Syncope.

The use of flibanserin can cause hypotension and syncope. The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension. Flibanserin should be used with caution in these patients.

Type 2 Diabetes

Moderate:

capivasertib

Capivasertib has a moderate potential interaction with Type 2 Diabetes.

Severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes, has occurred in patients treated with capivasertib. The safety of capivasertib in patients with Type 1 diabetes or with diabetes requiring insulin has not been established; these patients were excluded from clinical studies. Fasting blood glucose and hemoglobin A1C should be evaluated and optimized before starting treatment. Regular monitoring of fasting blood glucose as recommended by the manufacturer should be performed during treatment with capivasertib. Consider consultation with a specialist in the treatment of hyperglycemia and initiation of fasting glucose monitoring at home for patients who have risk factors for or who experience hyperglycemia. If hyperglycemia occurs during treatment, the dose of capivasertib may need to be withheld or reduced, or treatment permanently discontinued based on severity or if ketoacidosis is confirmed.

Report options

Loading...
QR code containing a link to this page

More resources

capivasertib

A total of 539 drugs are known to interact with capivasertib.

flibanserin

A total of 517 drugs are known to interact with flibanserin.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer